Streetbeat News

Price Targets

WOOF

Analysts have provided various ratings for Petco Health and Wellness (NASDAQ:WOOF) over the past quarter, with an average price target of $3.94, down from the previous $6.25. The ratings include 2 bullish, 3 somewhat bullish, and 2 indifferent. Notably, analysts from Jefferies, Morgan Stanley, RBC Capital, Goldman Sachs, Wedbush, and Needham have lowered their price targets. Petco's financial performance shows challenges with negative revenue trends, low net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:00 pm

CRNX

Crinetics Pharmaceuticals (NASDAQ:CRNX) received 4 analyst ratings in the last quarter, with an average 12-month price target of $44.25, down from the previous $52.00. Ratings include 1 bullish and 3 overweight, with price targets ranging from $35.00 to $50.00. The company's financial health shows challenges with a revenue decline of -24.45%, a net margin of -16606.36%, and ROE of -14.33%. Despite this, it maintains a low debt-to-equity ratio of 0.1.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:00 pm

ARVN

Arvinas Inc (NASDAQ:ARVN) has been analyzed by 9 analysts in the last quarter, with 4 bullish, 4 somewhat bullish, and 1 indifferent rating. The average 12-month price target is $38.44, down 15.39% from the previous $45.43. Analysts from firms like Wells Fargo, Jefferies, and Morgan Stanley have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Arvinas's financials show a revenue growth rate of 4.22% as of September 30, 2023, but lag behind industry peers. The company has a net margin of -184.97%, an ROE of -13.9%, an ROA of -5.98%, and a low debt-to-equity ratio of 0.01.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:00 pm

ETHUSD

Veteran commodities trader Peter Brandt predicts a significant drop in Ethereum (ETH) price, suggesting it could fall over 75% to $650. He notes that classical chart patterns, like the rising wedge currently seen in Ethereum's chart, are not always reliable but can indicate potential price targets. Brandt has shorted ETH and set a protective break-even stop. He also criticizes Ethereum for high transaction fees and questions its long-term viability as an asset.

Portfolio Pulse from Mehab Qureshi

December 19, 2023 | 1:00 pm

CRNX

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $42 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:43 pm

CTRA

Raymond James analyst John Freeman has maintained an Outperform rating on Coterra Energy (NYSE:CTRA) but has reduced the price target from $34 to $32.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:41 pm

IMNM

Wedbush analyst David Nierengarten has initiated coverage on Immunome (NASDAQ:IMNM) with an Outperform rating and set a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:40 pm

DVN

Raymond James analyst John Freeman has maintained an Outperform rating on Devon Energy (NYSE:DVN) but has reduced the price target from $61 to $53.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:39 pm

LEN

Raymond James analyst Buck Horne has maintained an Outperform rating on Lennar Corporation (NYSE:LEN) and increased the price target from $150 to $165.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:37 pm

NKE

Raymond James analyst Rick Patel has maintained an Outperform rating on Nike (NYSE:NKE) and increased the price target from $121 to $130.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:35 pm